

# David T Hagerty

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3275289/publications.pdf>

Version: 2024-02-01

6  
papers

521  
citations

1478505

6  
h-index

1872680

6  
g-index

6  
all docs

6  
docs citations

6  
times ranked

499  
citing authors

#	ARTICLE	IF	CITATIONS
1	A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis. Journal of Hepatology, 2020, 72, 816-827.	3.7	165
2	Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension. Journal of Hepatology, 2020, 72, 885-895.	3.7	107
3	Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non-alcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics, 2019, 49, 64-73.	3.7	77
4	Emricasan Improves Liver Function in Patients With Cirrhosis and High Model for End-Stage Liver Disease Scores Compared With Placebo. Clinical Gastroenterology and Hepatology, 2019, 17, 774-783.e4.	4.4	70
5	Emricasan (IDN6556) Lowers Portal Pressure in Patients With Compensated Cirrhosis and Severe Portal Hypertension. Hepatology, 2019, 69, 717-728.	7.3	68
6	Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis. Journal of Hepatology, 2021, 74, 274-282.	3.7	34